Adding NAC to OCD medication doesn't seem to help kids and teens better control their obsessive thoughts compared to just taking the medication alone.
Scientific Claim
N-acetylcysteine (NAC) added to citalopram does not significantly improve resistance to obsessions in children and adolescents with OCD compared to placebo, with a mean change of 1.8 (2.3) in the NAC group versus 0.8 (2.1) in the placebo group (P=0.2).
Original Statement
“The mean change of score of resistance/control to obsessions in the NAC and placebo groups was 1.8(2.3) and 0.8(2.1), respectively (P = 0.2).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
The study design supports causal inference, but the small sample size and high dropout rate limit precision. The study states 'no statistically significant decrease' but the evidence strength warrants 'may not significantly improve' to reflect uncertainty.
More Accurate Statement
“N-acetylcysteine (NAC) added to citalopram may not significantly improve resistance to obsessions in children and adolescents with OCD compared to placebo, with a mean change of 1.8 (2.3) in the NAC group versus 0.8 (2.1) in the placebo group (P=0.2).”
Evidence from Studies
Supporting (1)
Some psychometric properties of the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales (PedsQLTM) in the general Serbian population